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Abstract
Background: Antimicrobial resistance is a major public health pro-
blem worldwide. Numerous epidemiological studies reported that Le-
banon is affected with high levels of antibiotic resistance. The aim of 
this study is to determine the prevalence and antibiotic susceptibility 
patterns of carbapenem-resistant Gram-negative bacteria in North Le-
banon during the period 2015-2017.
Methods: Carbapenem-resistant Gram-negative bacteria were iso-
lated from patients referring to Nini hospital and Youssef hospital 
center. Identification and antibiotic susceptibility testing were perfor-
med through conventional tools according to the manufacturer’s re-
commended procedures and the recommendations of the European 
Committee on Antimicrobial Susceptibility Testing, respectively.
Results: Overall, a total of 290 carbapenem-resistant Gram-negative 
bacteria were isolated. Escherichia coli was predominant and repre-
sented 39.3% of all isolates, followed by Pseudomonas aeruginosa 
(24.8%), Acinetobacter baumannii (22.8%), Klebsiella spp. (8.6%), 
Enterobacter spp. (6.6%), Pantoea spp. (1%), and Proteus vulgaris 
(0.3%). Our findings showed an alarming increase in the prevalence of 
carbapenem resistant bacteria during the investigation period. On the 
other hand, colistin, tigecycline, amikacin and fosfomycin remain the 
most effective agents against carbapenem-resistant Gram-negative 
bacteria.
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Introduction
Antimicrobial resistance (AMR) is a major ongoing 
public health problem worldwide. A recent re-
port estimates that, by 2050, 10 million people 
will die every year due to AMR, and the major 
mortality cases will be from developing countries 
[1]. Unfortunately, high levels of AMR were repor-
ted in these countries, and were also associated 
with the emergence of pan-drug resistant (PDR) 
bacteria [2, 3]. The causes of AMR in middle and 
low income countries associated with complex is-
sues, including bad behaviors towards antibiotic 
use among both health care professionals and 
general population, limited diagnostic facilities, 
high spread of counterfeit medicines, excessive 
non-human use of antibiotics in food and agri-
culture, and absence of a national action plan for 
antimicrobial resistance [2].
Carbapenems are the most effective ß-lactams 
antibiotics presenting a broad spectrum of coverage 
against Gram-negative bacteria. However, Gram-
negative bacteria commonly recruit several mecha-
nisms to overcome the effect of these antibiotics. 
Resistance to carbapenems is mainly due to the pro-
duction of carbapenemases, the overexpression of 
efflux pumps, and the decrease in outer membrane 
permeability [4].
In Lebanon, as the majority of developing cou-
ntries, antibiotic resistance remains responsible for 
significant morbidity and mortality. Numerous epi-
demiological investigations have reported high le-
vels of antibiotic resistance among Gram-negative 
bacteria in our country in the last decade [5-15]. 
Recent studies reported the spread of carbapenem-
resistant strains in North Lebanon, mainly by OXA-
48 production [6, 7, 16-18]. In the same context, 
other carbapenemases (including NDM, VIM, IMP 
and OXA-type enzymes)were also reported in this 
area [5, 13, 16, 19-21].
Both rapid and reliable laboratory clinical investi-
gation and reporting are essential to guide clinicians 
including infectious diseases physicians to take ap-
propriate treatment decision which is critical to de-
crease treatment failure and to ensure the best pos-
sible outcome. Regrettably, rapid diagnostic tools 
are very limited in Lebanon, mainly due to financial 
reasons. The lack of these advanced diagnostic tools 
in association with poor infection control measures 
in a large number of healthcare facilities led to the 
spread of resistant bacteria at national level.
For these reasons, we conducted this investigation 
in order to determine the prevalence of carbapenem 
resistant Gram-negative bacteria isolated from pa-
tients referring to Nini hospital and Youssef hospital 
center in North Lebanon during the period 2015-
2017 and their antibiotic susceptibility patterns.
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Material and Methods
This study was conducted in the clinical microbiolo-
gy laboratories of Nini hospital (Tripoli, North gover-
norate) and Youssef hospital center (Halba, Akkar 
governorate) during the period from January 2015 
through to December 2017. Every hospital contains 
120 beds available to deliver high-quality patient 
care all in one center. Gram-negative bacteria were 
isolated on MacConkey Agar with crystal violet (Bio-
Rad®, France) from many types of specimen inclu-
ding respiratory, urine, blood, catheter, gastric juice, 
pus, wound, cornea, gallbladder, semen, and cere-
brospinal fluid samples. The bacterial identification 
was performed according to the manufacturer’s 
recommended procedures and through the use of 
API-20E and API-20NE (bioMérieux® - France). The 
antibiotic susceptibility testing was performed by 
the disk diffusion method on Mueller Hinton agar 
for Enterobacteriaceae and non-Enterobacteriaceae 
Gram-negative rods (Bio-Rad®, France) according to 
the recommendations of the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST). In 
addition, statistical analyses were performed with 
GraphPad Prism 6.0 (GraphPad Software Inc., San 
Diego, CA) using the Fisher’s exact test to confirm 
the increase in the prevalence of carbapenem resis-
tant Gram-negative bacteria including carbapenem-
resistant Enterobacteriaceae (CRE). The significance 
level considered for all statistical tests was a P-value 
< 0.05.
Results
A total of 6103 consecutive non-duplicate strains of 
Gram-negative bacteria were included in our study. 
Only Enterobacteriaceae resistant to ertapenem and 
Pseudomonas aeruginosa and Acinetobacter bau-
mannii resistant to imipenem and/or meropenem 
were included in this study. Hence, out of these 
isolates, 290 (4.75%) were carbapenem-resistant. 
Table 1 shows the major strains distribution based 
on type of specimen and hospital. Carbapenem-
resistant bacteria were mainly isolated from the fo-
llowing samples; urine (114/290; 39.3%), respiratory 
(82/290; 28.3%), and pus/wound (50/290; 17.2%). 
E. coli presented the highest infection rate (35.9%), 
followed by P. aeruginosa (24.8%), A. baumannii 
(22.8%), Klebsiella spp. (8.6%), Enterobacter spp. 
(6.6%), Pantoea spp. (1%), and Proteus vulgaris 
Table 1.  Distribution of carbapenem-resistant Gram-negative bacteria strains according to specimen origin.
Origin of 
specimen
Nini Hospital (Tripoli) Youssef Hospital Center (Halba)
Total
Enterobacteriaceae
P. aeruginosa / 
A.baumannii
Enterobacteriaceae
P. aeruginosa / 
A.baumannii
N % N % N % N % N %
Respiratory 33 39.8 10 17.9 6 8.7 33 40.2 82 28.3 
Urine 29 34.9 10 17.9 46 66.7 29 35.4 114 39.3 
Pus / Wound 12 14.4 13 23.2 12 17.4 13 15.9 50 17.3 
Blood 3 3.6 3 5.3 2 2.9 4 4.9 12 4.2 
Gallbladder 3 3.6 0 0 0 0 0 3 1.0 70.05
Catheter 2 2.4 12 21.4 0 0 2 2.4 16 5.5 
Semen 1 1.2 0 0 0 0 0 0 1 0.3 
Cornea 0 0 7 12.5 0 0 0 0 7 2.4 
Cerebrospinal fluid 0 0 1 1.8 0 0 0 0 1 0.3 
Gastric juice 0 0 0 3 4.3 1 1.2 4 1.4 
Total 83 100 56 100 69 100 82 100 290 100 
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Table 2.  Prevalence of carbapenem-resistant Gram-
negative bacteria according to the year of 
isolation.
Carbapenem-resistant Gram-negative bacteria
Gram-
negative 
bacteria 
Enterobacteriaceae
P. 
aeruginosa
A. 
baumannii
% % % %
2015 3.09 1.7 9.04 75
2016 4.52 1.71 14.93 82.35
2017 6.57 5.19 13.98 37.5
Total 3.9 2.8 12.8 66.7
Table 3.  Susceptibility profiles of carbapenem-resis-
tant Enterobacteriaceae strains isolated from 
two tertiary care hospitals in North Lebanon.
Escherichia 
coli
Klebsiella 
spp.
Enterobacter 
spp.
Pantoea 
spp.
Proteus 
vulgaris
Total
N=104 N=25 N=19 N=3 N=1 N=152
% % % % % %
AMP 0 0 0 0 0 0
TIC 0 0 5.3 0 0 0.7
PIP 0 0 5.3 0 0 0.7
AMC 1 4 0 0 0 1.3
TCC 3.8 4 10.5 0 0 4.6
PPT 3.8 4 15.8 0 0 5.2
CFX 6.7 4 0 0 0 5.2
CXM 16.3 12 0 0 0 13.1
FOX 31.7 28 5.3 0 0 27
CFM 17.3 20 5.3 0 0 15.8
CTX 19.2 20 10.5 0 0 17.7
CAZ 24 20 10.5 0 0 21
FEP 30.8 20 31.6 0 0 28.3
ATM 22.1 20 10.5 0 0 19.7
ERT 0 0 0 0 0 0
IMP 43.3 36 52.6 33.3 0 42.8
MEM 67.3 32 57.9 0 0 58.5
GMN 62.5 48 57.9 66.7 100 59.9
TMN 52.9 56 57.9 33.3 100 54
NET 74 64 73.7 66.7 100 72.3
AKN 92.3 72 78.9 66.7 100 86.8
NA 21.2 28 47.4 0 0 25
NXM 25 32 52.6 0 100 29.6
OFX 25 32 52.6 0 100 29.6
CIP 25 40 63.2 0 100 32.2
LVX 43.3 44 68.4 0 100 46.1
TET 10 25 33.3 0 NA 15.2
MNO 35.4 76 75 0 NA 46.4
TGC 94.2 80 84.2 100 NA 90.7
CS 100 100 100 100 NA 100
FSF 92.3 52 84.2 66.7 0 83.5
SXT 32.7 40 68.4 0 100 38.2
FUR 67.8 36 100 100 NA 67.2
*AMP, ampicillin (10 μg); TIC, ticarcillin (75 μg); PIP, piperacillin (30 μg); AMC, amoxicillin/
clavulanic acid (20/10 μg); TCC, ticarcillin/clavulanic acid (75/10 μg); PPT, piperacillin/tazobactam 
(30/4 μg); ATM, aztreonam (30 μg); IMP, imipenem (10 μg); MEM, meropenem (10 μg); ERT, 
ertapenem (10 μg); CFX, cefalexin (30 μg); CXM, cefuroxime (30 μg); FOX, cefoxitin (30 μg); CFM, 
cefixim (5 μg); CTX, cefotaxime (5 μg); FEP, cefepime (30 μg); CAZ, ceftazidime (30 μg); GMN, 
gentamicin (10 μg); TMN, tobramycin (10 μg); AKN, amikacin (30 μg); NET, netilmicin (10 μg); NA, 
nalidixic acid (30 μg); NXM, norfloxacin (10 μg); OFX, ofloxacin (5 μg); CIP, ciprofloxacin (5 μg); 
LVX, levofloxacin (5 μg); TET, tetracycline; MNO, minocycline; TGC, tigecycline (15 μg); CS, colistin 
(50 μg); FSF, fosfomycin (200 μg); SXT, trimethoprim/sulfamethoxazole (1,25/23,75 μg); FUR, 
nitrofurantoin (100 μg).
Figure 1:  Prevalence of carbapenem-resistant 
Gram-negative bacteria isolated from 
Nini hospital and Youssef hospital cen-
ter in 2015, 2016 and 2017.
*: P-value < 0.05.
(0.3%). The prevalence of carbapenem-resistant 
bacteria was alarmingly increased every year from 
3.09% in 2015 to 4.52% in 2016 (OR: 1.48, CI: 
1.07–2.07, P: 0.02) in comparison with data of 
2015 and 6.57% in 2017 (OR: 2.2, CI: 1.6–3.05, P< 
0.0001) in comparison with data of 2015 and (OR: 
1.48, CI: 1.14–1.93, P: 0.003) in comparison with 
data of 2016 . Besides, a significant increase in the 
prevalence of carbapenem-resistant Enterobacte-
riaceae was also found (OR: 3.15, CI: 2.04–4.88, P< 
0.0001) (Table 2 & Figure 1). Moreover, according 
to antimicrobial susceptibility tests and EUCAST 
guidelines, the mean percentage of sensitivity of 
all isolates was showed in Table 3 and 4. Briefly, out 
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of Enterobacteriaceae isolates, 41.5%, 57.2% and 
100% were resistant to meropenem, imipenem 
and ertapenem, respectively. The higher active an-
tibiotics against carbapenem-resistant Enterobacte-
riaceae were colistin (100%), tigecycline (90.7%), 
fosfomycin (83.5%), amikacin (83.5%), and nitrofu-
rantoin (67.2%). Moreover, high rates of resistance 
were detected to tetracycline (84.8%), minocycline 
(53.6%), nalidixic acid (75%), ciprofloxacin (67.8%), 
and co-trimoxazole (61.8%). Regarding A. bauman-
nii isolates, high rates of resistance were detected 
to aminoglycosides (97-98.5%), fluoroquinolones 
(100%), tetracycline (73.7%), and cotrimoxazole 
(73.7%). Furthermore, out of P. aeruginosa isolates, 
aztreonam was the most effective beta-lactam anti-
biotic (56.9%). However, the lower rates of activity 
were detected to fluoroquinolones (34.7%).
Discussion
The clinical microbiology laboratory has a crucial 
role in rapid detecting and reporting drug resistant 
bacteria to infectious disease specialists in order to 
choose appropriate antibiotic therapy. Multidrug 
resistant (MDR) bacteria such as carbapenem-re-
sistant pathogens are difficult to treat even when 
appropriate initial antibiotic therapy is used because 
they require different treatment regimens to tho-
se usually recommended in guidelines [22]. Hence, 
reliable treatment of MDR pathogens should be 
based on drug susceptibility testing since only few 
antibiotics remain as last-resort agents.
Furthermore, empirical treatment for patients 
who have risk factors to be infected by carbape-
nem-resistant pathogens should be based on the 
local available resistance data. Nevertheless, to our 
knowledge, few data are available in the literature 
regarding the antibiotic resistance patterns of car-
bapenem-resistant Gram-negative bacteria in the 
region of North Lebanon. Therefore, this investi-
gation aimed to provide important new laboratory 
data that could support specialists in infectious di-
seases in North Lebanon to take the appropriate 
decision in the treatment of patients infected with 
MDR germs. Overall, a total of 290 carbapenem 
resistant Gram-negative bacterial strains were iso-
lated from patients referred to two tertiary care 
hospitals in North Lebanon. A significant increase 
in the prevalence of carbapenem-resistant bacteria 
was found (Figure 1 & Table 2). The rise in pre-
valence of carbapenem-resistant isolates is mainly 
due to the overuse of carbapenem forced by the 
increase in percentage of ESBL-producing strains 
Table 4.  Susceptibility profiles of carbapenem-resis-
tant P. aeruginosa and A. baumannii stra-
ins isolated from two tertiary care hospitals 
in North Lebanon.
P. aeruginosa A. baumannii
N=72 N=66
% %
TIC 27.8 0
PIP 29.2 0
TCC 29.2 0
PPT 37.5 0
CTX NA 0
CAZ 41.7 0
FEP 40.3 0
ATM 56.9 NA
IMP 8.3 0
MEM 0 0
GMN 58.3 1.5
TMN 65.2 3
NET 61.1 1.5
AKN 65.2 3
CIP 34.7 0
LVX 34.7 0
TET NA 26.3
MNO NA 89.2
TGC NA 97.4
CS 100 100
FSF 84.7 NA
SXT NA 26.3
* TIC, ticarcillin (75 μg); PIP, piperacillin (30 μg) [100/10 μg for Acinetobacter baumannii]; 
TCC, ticarcillin/clavulanic acid (75/10 μg); PPT, piperacillin/tazobactam (30/6 μg) [100/10 
μg for Acinetobacter baumannii]; ATM, aztreonam (30 μg); IMP, imipenem (10 μg); MEM, 
meropenem (10 μg); FEP, cefepime (30 μg); CAZ, ceftazidime (10 μg); GMN, gentamicin (10 μg); 
TMN, tobramycin (10 μg); AKN, amikacin (30 μg); NET, netilmicin (10 μg); CIP, ciprofloxacin (5 
μg);LVX, levofloxacin (5 μg); TET, tetracycline; MNO, minocycline; TGC, tigecycline (15 μg); CS, 
colistin (50 μg); FSF, fosfomycin (200 μg); SXT, trimethoprim/sulfamethoxazole (1,25/23,75 μg).
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in the last decade in Lebanon [8]. Moreover, this 
alarming increase in carbapenem-resistance rate is 
a challenge that is associated with high morbidity 
and mortality [23]. According to our laboratory re-
cords, A. baumannii was the most resistant bacteria 
to carbapenem (66.7%), followed by P. aeruginosa 
(12.8%) and Enterobacteriaceae (2.8%). These data 
are in the range of previous reports conducted in 
the same geographical region [8, 14]. Moreover, 
our findings highlight the importance of tackling 
AMR across medical and non-medical sectors in or-
der to prevent the emergence and spread of PDR 
bacterial clones in Lebanon. A recent nationwide 
cross-sectional study showed a striking low level of 
antibiotic knowledge among Lebanese population 
and confirmed the crucial role of awareness to re-
inforce the key messages about the appropriate use 
of antibiotics [24]. However, despite the importance 
of such initiative, this movement should be suppor-
ted with further awareness campaigns and pressure 
movements to implement policy-based changes.
On the other hand, the antibiotic susceptibility 
testing showed that colistin was the most active 
antibiotic against carbapenem-resistant bacteria. 
Despite the high renal and neurological side effects 
of colistin, this antibiotic is used as first option in 
combination therapy due to its clinical importance 
[25]. However, most of Lebanese routine laborato-
ries uses the standard disc antimicrobial susceptibi-
lity method for testing this compound. 
The disk diffusion method does not work pro-
perly due to the poor diffusion of the large colistin 
molecule and the failure to detect the majority of 
resistant strains [26]. 
In addition, tigecycline has also been recom-
mended as part of the combination regimen in the 
treatment of cases with carbapenem resistant En-
terobacteriaceae and A. baumannii. This study de-
monstrates that tigecycline was the second most 
active compound against Enterobacteriaceae and 
to less extent against A. baumannii. However, this 
antibiotic is used to treat infections in different body 
sites, other than urinary tract and bloodstream in-
fections. The second generation of tetracycline 
family (minocycline) was also active, but with less 
percentage of activity against the recorded bacteria 
isolates. Tetracycline was only active against 15.2% 
and 26.3% of carbapenem-resistant Enterobacte-
riaceae and A. baumannii, respectively. This study 
indicates a very low rate of tigecycline resistance 
against carbapenem-resistant isolates in Lebanon 
as it has been observed in previous reports [8, 12, 
14, 27].
Furthermore, aminoglycosides and fosfomycin 
families showed a good activity against the isola-
tes. Interestingly, amikacin had the higher activity 
compared to netilmicin, gentamicin and tobramycin 
against carbapenem-resistant Gram-negative bacte-
ria. Out of 290 isolates, amikacin was the third most 
active compound against both Enterobacteriaceae 
and P. aeruginosa. In contrast, very high levels of 
aminoglycoside resistance (97%-98.5%) were de-
tected among carbapenem-resistant A. baumannii. 
Recently, a clinical study showed that fosfomycin is 
active in combination with colistin or tigecycline in 
the treatment of invasive infections caused by ex-
tensively drug-resistant (XDR) and PDR Enterobacte-
riaceae and P. aeruginosa strains [28]. The prevalen-
ce of fosfomycin-resistant Enterobacteriaceae was 
close to that found in previous studies conducted in 
the same geographic region, where 15% and 11% 
of strains isolated from ear infections [11] and uri-
nary tract infections [14], respectively, were resistant 
to fosfomycin.
The present study shows that quinolones, levo-
floxacin was the most active among the tested com-
pounds. Levofloxacin and ciprofloxacin resistance 
rates among Enterobacteriaceae and P. aeruginosa 
isolates were higher than other tested antibiotic fa-
milies, but they were within the range of previous 
Lebanese studies [8, 11, 12, 14]. Surprisingly, no A. 
baumannii strain was susceptible to fluoroquinolo-
nes. This alarming high rates of fluoroquinolone re-
sistance could be explained by the extensive misuse 
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and overuse of this class of antibiotics in our coun-
try. In addition to unauthorized sale of fluoroquino-
lones in pharmacies and inadequate use by general 
population, this family of antibiotics is extensively 
prescribed by Lebanese physicians.
In conclusion, this study indicates an alarming in-
crease in the prevalence of carbapenem- resistant 
Gram-negative bacteria in North Lebanon. Our 
findings are crucial to guide clinicians for selection 
of optimal antibiotic treatment. To date, colistin, 
tigecycline, amikacin and fosfomycin remain the 
most effective agents against carbapenem-resistant 
Gram-negative bacteria. Therefore, we have a major 
challenge to combat AMR by forcing the implemen-
tation of efficient infection control measures and 
antibiotic stewardship programs in clinical settings 
and increasing the public awareness on this issue.
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